Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2 1

Status

Recruiting 11Not yet recruiting 11Unknown 10Completed 3Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

NSCLC 1

Interventions

pembrolizumab 197Nivolumab 145Carboplatin 135Specimen Handling 130Magnetic Resonance Spectroscopy 116Cyclophosphamide 111Paclitaxel 107Cisplatin 97Biopsy 97Radiotherapy 89durvalumab 82Dexamethasone 80atezolizumab 74Ipilimumab 63Gemcitabine 61Rituximab 59Doxorubicin 59Lenalidomide 56Docetaxel 56olaparib 53Bevacizumab 51Capecitabine 50Fluorouracil 49Etoposide 49Radiation 46Oxaliplatin 46Radiosurgery 43venetoclax 42Prednisone 42Taxes 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × aflutinib × Clear all
NCT05466149 2025-11-19

Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

Allist Pharmaceuticals, Inc.

Phase 2 Active not recruiting
100 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡